ZKEM PR
BW2345 JUL 31,2001 6:31 PACIFIC 09:31 EASTERN
( BW)(NJ-XECHEM-INTERNATIONAL)(ZKEM) Xechem International, Inc. Brings Three New Members To Its Board Of Directors
Business Editors
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--July 31, 2001--Xechem International Inc. (OTC BB ZKEM) proposed and announced at its Annual Stockholder's meeting on July 09, 2001 the election and appointment of John P. Luther, Esq., Jed C. Goldart, M.D., M.P.H., and Neil M. Kosterman to its board.
Dr. Ramesh C. Pandey, the President & CEO of Xechem stated, "we are very happy that all three of these gentleman are aboard with Xechem. This significantly strengthens our Board and leadership. Mr. Luther has been working with the Company for the past seven years in private practice as intellectual property law and litigation counsel for Xechem and he has now come aboard full-time as Vice President & General Council and Director. Dr. Goldart is a board certified psychiatrist with training in public health and administration. His background both as a practicing clinician and as a physician executive responsible for building and managing large, national level health care systems serving millions of consumers nationwide adds a broad health care system perspective to the Company's strategic planning resources. In addition, he brings his broad experience as a health care marketing and communications consultant serving the pharmaceutical/nutraceutical and medical device manufacturing industries. Mr. Neil M. Kosterman, who has also joined Xechem's Board, has three decades of experience in the medical and pharmaceutical products industry with a particular emphasis on marketing and business development. Mr. Kosterman spent his first two decades as an executive with Datek/Ohmeda, C.R. Bard, Pfizer and Smith & Nephew in marketing and general management. The last 10 years have been spent emphasizing turnaround situations and startups through his consulting company, DeltaQuest LLC. He has been a founder and co-founder of several startup companies, as well having been a licensing consultant for the technology transfer office of the University of Wisconsin in Madison."
Xechem International, Inc., (www.xechem.com) headquartered in New Brunswick, NJ, with subsidiary companies in USA, India and joint venture partners in both Hong Kong and Peoples Republic of China, is a biopharmaceutical company of which Xechem, Inc. (a US subsidiary) is engaged in the research, development and production of generic and proprietary drugs from natural sources, specializing in the development of niche-generic, difficult to replicate anticancer drugs, most notably paclitaxel, the most widely prescribed cancer drug in the USA, antiviral (including Human Immuno-deficiency Virus, HIV), antifungal and anti-infective compounds and screens extracts and pure compounds from various parts of the world for their therapeutic use. XetaPharm, Inc., a subsidiary of Xechem, develops quality controlled nutritional products such as GinkgoOnce(R), GinsengOnce(R), GarlicOnce(R), Gugulon(TM), Co-Enzyme Q-10 and VIDA PRAS(TM) as well as numerous other products under development. All XetaPharm products can be seen and ordered from our website at www.xetapharm.com, at our toll-free number (1-800-858-5854) or through a growing number of pharmacies, health food and nutritional stores.
This news release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks, uncertainties, including the ability of the Companies to successfully develop and commercialize their technologies, and other factors that may cause the actual results, performance or achievements of the Companies to be materially different from any future results, performance or achievements of the Companies expressed or implied by such forward-looking statements.
